Replimune/$REPL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Replimune
Replimune Group Inc is a clinical-stage biotechnology company committed to applying its expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients through novel oncolytic immunotherapies. Its proprietary oncolytic immunotherapy product candidates are designed and intended to maximally activate the immune system against cancer. Oncolytic immunotherapy is an emerging drug class. The proprietary RPx platform is based on a novel, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added that are intended to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. It operates in single segment of developing oncolytic immunotherapies for the treatment of cancer.
- Ticker
- $REPL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 465
- Headquarters
- Woburn, United States
- Website
- www.replimune.com
Replimune Metrics
BasicAdvanced
$1B
-
-$3.15
0.94
-
Price and volume
Market cap
$1B
Beta
0.94
52-week high
$16.33
52-week low
$1.50
Average daily volume
2.1M
Financial strength
Current ratio
5.228
Quick ratio
5.085
Long term debt to equity
1.022
Total debt to equity
1.06
Interest coverage (TTM)
-29.78%
Profitability
EBITDA (TTM)
-290.44
Effective tax rate (TTM)
0.19%
Management effectiveness
Return on assets (TTM)
-51.30%
Return on equity (TTM)
-134.29%
Valuation
Price to book
8.63
Price to tangible book (TTM)
8.63
Price to free cash flow (TTM)
-3.644
Free cash flow yield (TTM)
-27.44%
Free cash flow per share (TTM)
-2.98
Growth
Earnings per share change (TTM)
-12.40%
3-year earnings per share growth (CAGR)
2.10%
What the Analysts think about Replimune
Analyst ratings (Buy, Hold, Sell) for Replimune stock.
Analyst projections of the future price of Replimune stock.
Bulls say / Bears say
The RP1 combination has shown potentially durable activity in a hard-to-treat group: 47.8% of all treated patients were alive at three years, with median overall survival of 32.9 months. An FDA advisory committee also voted 10-3 that the efficacy results were evaluable and clinically meaningful. (Replimune, Replimune)
The FDA previously said RP1's single-arm trial made it unclear whether the drug itself drove the tumour responses, and warned that the reported response rate might be artificially inflated. That leaves the strength of the approval evidence disputed despite the eventual authorisation. (Reuters)
TUDRIQEV's accelerated approval depends on a confirmatory trial proving clinical benefit, so it is not fully de-risked. Replimune says the Phase 3 trial's primary overall-survival readout is expected in 2030, leaving a long period in which a failed study could threaten the approval. (Replimune, Last10K)
The business remains cash-burning as it moves into commercialisation: Replimune reported a $69.8 million quarterly net loss and said more than 12 months of funding included $141 million of net proceeds from a common-stock issue. Further development and launch costs could therefore bring more financing needs and shareholder dilution. (Last10K)
Data summarised monthly by Lightyear AI. Last updated on 23 Sept 2026.
Replimune Financial Performance
Revenues and expenses
Replimune Earnings Performance
Company profitability
Upcoming events
No upcoming events
Replimune News
AllArticlesVideos
Robbins LLP is Investigating Allegations that Replimune Group, Inc. Misled Investors Regarding the Efficacy and Viability of its Lead Product Candidate RP1
Newsfile Corp3 weeks ago
Bronstein, Gewirtz & Grossman LLC Urges Replimune Group, Inc. Investors to Act: Class Action Filed Alleging Investor Harm
Newsfile Corp1 month ago
REPL Shareholder Alert: October 5, 2026 Lead Plaintiff Deadline in Replimune Group, Inc. Securities Class Action - Contact Levi & Korsinsky
Business Wire1 month ago
Funds containing Replimune
AllUSDGBPEUR
Fund name | Fund size | $REPL weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.07% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.07% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.03% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.03% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.